# Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

> **NCT02697838** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 20 (actual)

## Conditions studied

- Malignant Neoplasm of Stomach Stage II

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Paclitaxel-based chemotherapeutic regimens

## Key facts

- **NCT ID:** NCT02697838
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08-01
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697838, "Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02697838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*